These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30649837)

  • 1. The Promising Viral Threat to Bacterial Resistance: the Uncertain Patentability of Phage Therapeutics and the Necessity of Alternative Incentives.
    Todd K
    Duke Law J; 2019 Jan; 68(4):767-805. PubMed ID: 30649837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 5. Where have all the antibiotic patents gone?
    Katz ML; Mueller LV; Polyakov M; Weinstock SF
    Nat Biotechnol; 2006 Dec; 24(12):1529-31. PubMed ID: 17160057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract]   [Full Text] [Related]  

  • 8. A cheat sheet to navigate the complex maze of exclusivities in the United States.
    Peng B; Tomas MC
    Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
    [No Abstract]   [Full Text] [Related]  

  • 9. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 11. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bacteriophages in the battle against multidrug resistant bacteria].
    van der Meer JWM; Vandenbroucke-Grauls CMJE
    Ned Tijdschr Geneeskd; 2018; 162():D2433. PubMed ID: 29600928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary patents in the pharmaceutical industry: missing the wood for the trees?
    Kiran S; Kulkarni M
    Expert Opin Ther Pat; 2018 Mar; 28(3):241-250. PubMed ID: 29298119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
    Furfaro LL; Payne MS; Chang BJ
    Front Cell Infect Microbiol; 2018; 8():376. PubMed ID: 30406049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Magistral Phage.
    Pirnay JP; Verbeken G; Ceyssens PJ; Huys I; De Vos D; Ameloot C; Fauconnier A
    Viruses; 2018 Feb; 10(2):. PubMed ID: 29415431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
    Levi EL
    Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.